Publications en modélisation

256 publications au 01/05/2016


2016Salem JE, El-Aissaoui M, Alazard M, Hulot JS, Aissaoui N, Le-Heuzey JY, Funck-Brentano C, Faisy C, Urien S.Modeling of Amiodarone Effect on Heart Rate Control in Critically Ill Patients with Atrial Tachyarrhythmias.pubmed
2016Vinot C, Treluyer JM, Giraud C, Gavard L, Peytavin G, Mandelbrot L.Bidirectional Transfer of Raltegravir in an Ex Vivo Human Cotyledon Perfusion Model.pubmed
2016Homkham N, Cressey TR, Ingsrisawang L, Bouazza N, Ngampiyaskul C, Hongsiriwon S, Srirojana S, Kanjanavanit S, Bhakeecheep S, Coeur SL, Salvadori N, Treluyer JM, Jourdain G, Urien S.A Population Pharmacokinetic/Pharmacodynamic Model Predicts Favorable HDL Cholesterol Changes Over the First 5 Years in Children Treated with Current Efavirenz-Based Regimens.pubmed
2015Lafont E, Urien S, Salem JE, Heming N, Faisy C.Modeling for critically ill patients: An introduction for beginners.pubmed
2015Alberini JL, Boisgard R, Guillermet S, Siquier K, Jego B, Theze B, Urien S, Rezaï K, Menet E, Maroy R, Dolle F, Kühnast B, Tavitian B.Multimodal In Vivo Imaging of Tumorigenesis and Response to Chemotherapy in a Transgenic Mouse Model of Mammary Cancer.pubmed
2016De Sousa Mendes M, Hirt D, Vinot C, Valade E, Lui G, Pressiat C, Bouazza N, Foissac F, Blanche S, Lê MP, Peytavin G, Treluyer JM, Urien S, Benaboud S.Prediction of human fetal pharmacokinetics using ex vivo human placenta perfusion studies and physiologically based models.pubmed
2015Sripan P, Le Coeur S, Ingsrisawang L, Cressey TR, Bouazza N, Foissac F, Ngo-Giang-Huong N, Traisathit P, Srirompotong U, Ayudhaya OP, Puangsombat A, Jungpipun J, Jittayanun K, Treluyer JM, Jourdain G, Lallemant M, Urien S.Contribution of different antiretroviral regimens containing zidovudine, lamivudine and ritonavir-boosted lopinavir on HIV viral load reduction during pregnancy.pubmed
2015Valade E, Treluyer JM, Illamola SM, Bouazza N, Foissac F, De Sousa Mendes M, Lui G, Chenevier-Gobeaux C, Suzan-Monti M, Rouzioux C, Assoumou L, Viard JP, Hirt D, Urien S, Ghosn J; Evarist ANRS-EP 49 Study Group.Emtricitabine seminal plasma and blood plasma population pharmacokinetics in HIV-infected men in the EVARIST ANRS-EP 49 study.pubmed
2015Wolahan SM, Hirt D, Glenn TC.Translational Metabolomics of Head Injury: Exploring Dysfunctional Cerebral Metabolism with Ex Vivo NMR Spectroscopy-Based Metabolite Quantification.pubmed
2016Bouazza N, Urien S, Neven B, Moshous D, Nisoy J, Gabrion A, Cavazzana M, Blanche S, Treluyer JM, Touzot F.Evaluation of antithymocyte globulin pharmacokinetics and pharmacodynamics in children.pubmed
2015Fauchet F, Treluyer JM, Illamola SM, Pressiat C, Lui G, Valade E, Mandelbrot L, Lechedanec J, Delmas S, Blanche S, Warszawski J, Urien S, Tubiana R, Hirt D.Population approach to analyze the pharmacokinetics of free and total lopinavir in HIV-infected pregnant women and consequences for dose adjustment.pubmed
2015De Sousa Mendes M, Hirt D, Urien S, Valade E, Bouazza N, Foissac F, Blanche S, Treluyer JM, Benaboud S.Physiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women.pubmed
2015Sripan P, Le Coeur S, Amzal B, Ingsrisawang L, Traisathit P, Ngo-Giang-Huong N, McIntosh K, Cressey TR, Sangsawang S, Rawangban B, Kanjanavikai P, Treluyer JM, Jourdain G, Lallemant M, Urien S.Modeling of In-Utero and Intra-Partum Transmissions to Evaluate the Efficacy of Interventions for the Prevention of Perinatal HIV.pubmed
2015Foissac F, Bouazza N, Valade E, De Sousa Mendes M, Fauchet F, Benaboud S, Hirt D, Treluyer JM, Urien S.Prediction of drug clearance in children.pubmed
2015Sirirungsi W, Urien S, Harrison L, Kamkon J, Tawon Y, Luekamlung N, Thongpaen S, Nilmanat A, Jourdain G, Lallemant M, Le Coeur S, Ngo-Giang-Huong N, Owen A, Cressey TR.No relationship between drug transporter genetic variants and tenofovir plasma concentrations or changes in glomerular filtration rate in HIV-infected adults.pubmed
2015Illamola SM, Hirt D, Treluyer JM, Urien S, Benaboud S.Challenges regarding analysis of unbound fraction of highly bound protein antiretroviral drugs in several biological matrices: lack of harmonisation and guidelines.pubmed
2014Courbebaisse M, Alberti C, Colas S, Prie D, Souberbielle JC, Treluyer JM, Thervet E.VITamin D supplementation in renAL transplant recipients (VITALE): a prospective, multicentre, double-blind, randomized trial of vitamin D estimating the benefit and safety of vitamin D3 treatment at a dose of 100,000 UI compared with a dose of 12,000 UI in renal transplant recipients: study protoco...pubmed
2015Bouazza N, Foissac F, Fauchet F, Burger D, Kiechel JR, Treluyer JM, Capparelli EV, Lallemant M, Urien S.Lopinavir/ritonavir plus lamivudine and abacavir or zidovudine dose ratios for paediatric fixed-dose combinations.pubmed
2015Cressey TR, Urien S, Capparelli EV, Best BM, Buranabanjasatean S, Limtrakul A, Rawangban B, Sabsanong P, Treluyer JM, Jourdain G, Stek A, Lallemant M, Mirochnick M.Impact of body weight and missed doses on lopinavir concentrations with standard and increased lopinavir/ritonavir doses during late pregnancy.pubmed
2014Lloret-Linares C, Hirt D, Bardin C, Bouillot JL, Oppert JM, Poitou C, Chast F, Mouly S, Scherrmann JM, Bergmann JF, Declèves X.Effect of a Roux-en-Y gastric bypass on the pharmacokinetics of oral morphine using a population approach.pubmed
2014Mangin O, Urien S, Mainardi JL, Fagon JY, Faisy C.Vancomycin pharmacokinetic and pharmacodynamic models for critically ill patients with post-sternotomy mediastinitis.pubmed
2014Fauchet F, Treluyer JM, Preta LH, Valade E, Pannier E, Urien S, Hirt D.Population pharmacokinetics of abacavir in pregnant women.pubmed
2014Fauchet F, Treluyer JM, Valade E, Benaboud S, Pannier E, Firtion G, Foissac F, Bouazza N, Urien S, Hirt D.Maternal and fetal zidovudine pharmacokinetics during pregnancy and labour: too high dose infused at labour?pubmed
2014Valade E, Treluyer JM, Dabis F, Arrive E, Pannier E, Benaboud S, Fauchet F, Bouazza N, Foissac F, Urien S, Hirt D.Modified renal function in pregnancy: impact on emtricitabine pharmacokinetics.pubmed
2014Foissac F, Meyzer C, Frange P, Chappuy H, Benaboud S, Bouazza N, Friedlander G, Souberbielle JC, Urien S, Blanche S, Treluyer JM.Determination of optimal vitamin D3 dosing regimens in HIV-infected paediatric patients using a population pharmacokinetic approach.pubmed
2014Oualha M, Treluyer JM, Lesage F, de Saint Blanquat L, Dupic L, Hubert P, Spreux-Varoquaux O, Urien S.Population pharmacokinetics and haemodynamic effects of norepinephrine in hypotensive critically ill children.pubmed
2014Daher Abdi Z, Lavau-Denes S, Premaud A, Urien S, Sauvage FL, Martin J, Leobon S, Marquet P, Tubiana-Mathieu N, Rousseau A.Pharmacokinetics and exposure-effect relationships of capecitabine in elderly patients with breast or colorectal cancer.pubmed
2014Bouazza N, Treluyer JM, Ghosn J, Hirt D, Benaboud S, Foissac F, Viard JP, Urien S.Evaluation of effect of impaired renal function on lamivudine pharmacokinetics.pubmed
2014Rigourd V, de Villepin B, Amirouche A, Bruneau A, Seraissol P, Florent A, Urien S, Magny JF, Serreau R.Ibuprofen concentrations in human mature milk--first data about pharmacokinetics study in breast milk with AOR-10127 Antalait" study."pubmed
2014Bouazza N, Urien S, Blanche S, Hirt D, Foissac F, Benaboud S, Treluyer JM, Frange P.Concentration-response model of lopinavir/ritonavir in HIV-1-infected pediatric patients.pubmed
2014Valade E, Treluyer JM, Bouazza N, Ghosn J, Foissac F, Benaboud S, Fauchet F, Viard JP, Urien S, Hirt D.Population pharmacokinetics of emtricitabine in HIV-1-infected adult patients.pubmed
2014Heming N, Urien S, Fulda V, Meziani F, Gacouin A, Clavel M, Planquette B, Faisy C.Population pharmacodynamic modeling and simulation of the respiratory effect of acetazolamide in decompensated COPD patients.pubmed
2014Oualha M, Urien S, Spreux-Varoquaux O, Bordessoule A, D'Agostino I, Pouard P, Treluyer JM.Pharmacokinetics, hemodynamic and metabolic effects of epinephrine to prevent post-operative low cardiac output syndrome in children.pubmed
2014Oualha M, Capelo M, Spreux-Varoquaux O, Drouet-Chaillou I, Treluyer JM, Hubert P, Lesage F.Delay and stability of central venous administration of norepinephrine in children: a bench study.pubmed
2013Urien S, Bardin C, Bader-Meunier B, Mouy R, Compeyrot-Lacassagne S, Foissac F, Florkin B, Wouters C, Neven B, Treluyer JM, Quartier P.Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes.pubmed
2013Grassin-Delyle S, Tremey B, Abe E, Fischler M, Alvarez JC, Devillier P, Urien S.Population pharmacokinetics of tranexamic acid in adults undergoing cardiac surgery with cardiopulmonary bypass.pubmed
2013Fauchet F, Treluyer JM, Frange P, Urien S, Foissac F, Bouazza N, Benaboud S, Blanche S, Hirt D.Population pharmacokinetics study of recommended zidovudine doses in HIV-1-infected children.pubmed
2013Bouazza N, Treluyer JM, Msellati P, Van de Perre P, Diagbouga S, Nacro B, Hien H, Zoure E, Rouet F, Ouiminga A, Blanche S, Hirt D, Urien S.A novel pharmacokinetic approach to predict virologic failure in HIV-1-infected paediatric patients.pubmed
2013Patnaik A, Papadopoulos KP, Tolcher AW, Beeram M, Urien S, Schaaf LJ, Tahiri S, Bekaii-Saab T, Lokiec FM, Rezaï K, Buchbinder A.Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer.pubmed
2013Hirt D, Warszawski J, Firtion G, Giraud C, Chappuy H, Lechenadec J, Benaboud S, Urien S, Blanche S, Treluyer JM.High exposure to zidovudine during the first 2 weeks of life and concentration-toxicity relationships.pubmed
2012Schlegel A, Buhler C, Devun F, Agrario C, Urien S, Lokiec F, Sun JS, Dutreix M.Pharmacokinetics and Toxicity in Rats and Monkeys of coDbait: A Therapeutic Double-stranded DNA Oligonucleotide Conjugated to Cholesterol.pubmed
2013Grassin-Delyle S, Couturier R, Abe E, Alvarez JC, Devillier P, Urien S.A practical tranexamic acid dosing scheme based on population pharmacokinetics in children undergoing cardiac surgery.pubmed
2013Vinot C, Gavard L, Treluyer JM, Manceau S, Courbon E, Scherrmann JM, Declèves X, Duro D, Peytavin G, Mandelbrot L, Giraud C.Placental transfer of maraviroc in an ex vivo human cotyledon perfusion model and influence of ABC transporter expression.pubmed
2013Foissac F, Bouazza N, Frange P, Blanche S, Faye A, Lachassinne E, Dollfus C, Hirt D, Benaboud S, Treluyer JM, Urien S.Evaluation of nevirapine dosing recommendations in HIV-infected children.pubmed
2012Berveiller P, Vinot C, Mir O, Broutin S, Deroussent A, Seck A, Camps S, Paci A, Gil S, Treluyer JM.Comparative transplacental transfer of taxanes using the human perfused cotyledon placental model.pubmed
2012Lemaitre F, Bezian E, Goldwirt L, Fernandez C, Farinotti R, Varnous S, Urien S, Antignac M.Population pharmacokinetics of everolimus in cardiac recipients: comedications, ABCB1, and CYP3A5 polymorphisms.pubmed
2013Foissac F, Treluyer JM, Souberbielle JC, Rostane H, Urien S, Viard JP.Vitamin D3 supplementation scheme in HIV-infected patients based upon pharmacokinetic modelling of 25-hydroxycholecalciferol.pubmed
2013Benaboud S, Urien S, Thervet E, Prie D, Legendre C, Souberbielle JC, Hirt D, Friedlander G, Treluyer JM, Courbebaisse M.Determination of optimal cholecalciferol treatment in renal transplant recipients using a population pharmacokinetic approach.pubmed
2012Kurzrock R, Goel S, Wheler J, Hong D, Fu S, Rezai K, Morgan-Linnell SK, Urien S, Mani S, Chaudhary I, Ghalib MH, Buchbinder A, Lokiec F, Mulcahy M.Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies.pubmed
2012Manceau S, Giraud C, Declèves X, Batteux F, Chereau C, Chouzenoux S, Scherrmann JM, Weill B, Perrot JY, Treluyer JM.Expression and induction by dexamethasone of ABC transporters and nuclear receptors in a human T-lymphocyte cell line.pubmed
2012Bouazza N, Pestre V, Jullien V, Curis E, Urien S, Salmon D, Treluyer JM.Population pharmacokinetics of clindamycin orally and intravenously administered in patients with osteomyelitis.pubmed
2012Grosjean P, Urien S.Moxifloxacin versus placebo modeling of the QT interval.pubmed
2012Bardin C, Nobecourt E, Larger E, Chast F, Treluyer JM, Urien S.Population pharmacokinetics of metformin in obese and non-obese patients with type 2 diabetes mellitus.pubmed
2011Bouazza N, Treluyer JM, Ottolenghi C, Urien S, Deschenes G, Ricquier D, Niaudet P, Chadefaux-Vekemans B.Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients.pubmed
2012Benaboud S, Hirt D, Launay O, Pannier E, Firtion G, Rey E, Bouazza N, Foissac F, Chappuy H, Urien S, Treluyer JM.Pregnancy-related effects on tenofovir pharmacokinetics: a population study with 186 women.pubmed
2012Benaboud S, Treluyer JM, Urien S, Blanche S, Bouazza N, Chappuy H, Rey E, Pannier E, Firtion G, Launay O, Hirt D.Pregnancy-related effects on lamivudine pharmacokinetics in a population study with 228 women.pubmed
2012Berveiller P, Mir O, Vinot C, Bonati C, Duchene P, Giraud C, Gil S, Treluyer JM.Transplacental transfer of oseltamivir and its metabolite using the human perfused placental cotyledon model.pubmed
2011Heming N, Faisy C, Urien S.Population pharmacodynamic model of bicarbonate response to acetazolamide in mechanically ventilated chronic obstructive pulmonary disease patients.pubmed
2011Bouazza N, Urien S, Hirt D, Frange P, Rey E, Benaboud S, Foissac F, Blanche S, Treluyer JM.Population pharmacokinetics of tenofovir in HIV-1-infected pediatric patients.pubmed
2011Foissac F, Urien S, Hirt D, Frange P, Chaix ML, Treluyer JM, Blanche S.Pharmacokinetics and virological efficacy after switch to once-daily lopinavir-ritonavir in treatment-experienced HIV-1-infected children.pubmed
2011Nacro B, Zoure E, Hien H, Tamboura H, Rouet F, Ouiminga A, Drabo A, Yameogo S, Hien A, Peyriere H, Mathieu O, Hirt D, Treluyer JM, Nicolas J, Foulongne V, Segondy M, van de Perre P, Diagbouga S, Msellati P.Pharmacology and immuno-virologic efficacy of once-a-day HAART in African HIV-infected children: ANRS 12103 phase II trial.pubmed
2011Foissac F, Blanche S, Dollfus C, Hirt D, Firtion G, Laurent C, Treluyer JM, Urien S.Population pharmacokinetics of atazanavir/ritonavir in HIV-1-infected children and adolescents.pubmed
2011Bazzoli C, Benech H, Rey E, Retout S, Salmon D, Duval X, Treluyer JM, Mentre F; COPHAR2-ANRS 111 Study Group.Joint population pharmacokinetic analysis of zidovudine, lamivudine, and their active intracellular metabolites in HIV patients.pubmed
2011Bouazza N, Hirt D, Blanche S, Frange P, Rey E, Treluyer JM, Urien S.Developmental pharmacokinetics of lamivudine in 580 pediatric patients ranging from neonates to adolescents.pubmed
2011Urien S, Firtion G, Anderson ST, Hirt D, Solas C, Peytavin G, Faye A, Thuret I, Leprevost M, Giraud C, Lyall H, Khoo S, Blanche S, Treluyer JM.Lopinavir/ritonavir population pharmacokinetics in neonates and infants.pubmed
2011Rezai K, Urien S, Isambert N, Roche H, Dieras V, Berille J, Bonneterre J, Brain E, Lokiec F.Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients.pubmed
2011Megarbane B, Hirt D, Bloch V, Baud FJ.Epinephrine requirement based on the reported ingested dose in chloroquine poisoning: usefulness and limitations of dose-effect modelling.pubmed
2011Hirt D, Ekouevi DK, Pruvost A, Urien S, Arrive E, Blanche S, Avit D, Amani-Bosse C, Nyati M, Legote S, Ek ML, Say L, McIntyre J, Dabis F, Treluyer JM.Plasma and intracellular tenofovir pharmacokinetics in the neonate (ANRS 12109 trial, step 2).pubmed
2011Hirt D, Pruvost A, Ekouevi DK, Urien S, Arrive E, Kone M, Nerrienet E, Nyati M, Gray G, Kruy LS, Blanche S, Dabis F, Treluyer JM.Very high concentrations of active intracellular phosphorylated emtricitabine in neonates (ANRS 12109 trial, step 2).pubmed
2012Grosjean P, Urien S.Reevaluation of moxifloxacin pharmacokinetics and their direct effect on the QT interval.pubmed
2011Antignac M, Fernandez C, Barrou B, Roca M, Favrat JL, Urien S, Farinotti R.Prediction tacrolimus blood levels based on the Bayesian method in adult kidney transplant patients.pubmed
2011Cressey TR, Urien S, Hirt D, Halue G, Techapornroong M, Bowonwatanuwong C, Leenasirimakul P, Treluyer JM, Jourdain G, Lallemant M; PHPT-3 Team.Influence of body weight on achieving indinavir concentrations within its therapeutic window in HIV-infected Thai patients receiving indinavir boosted with ritonavir.pubmed
2011Tao Y, Rezaï K, Brain E, Etessami A, Lusinchi A, Temam S, Urien S, Van ML, Vauzelle-Kervroedan F, Lokiec F, Daly-Schveitzer N, Bourhis J.A phase I trial combining oral cisplatin (CP Ethypharm) with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma.pubmed
2010Megarbane B, Bloch V, Hirt D, Debray M, Resiere D, Deye N, Baud FJ.Blood concentrations are better predictors of chioroquine poisoning severity than plasma concentrations: a prospective study with modeling of the concentration/effect relationships.pubmed
2011Premaud A, Weber LT, Tönshoff B, Armstrong VW, Oellerich M, Urien S, Marquet P, Rousseau A.Population pharmacokinetics of mycophenolic acid in pediatric renal transplant patients using parametric and nonparametric approaches.pubmed
2011Vial Y, Tod M, Hornecker M, Urien S, Conti F, Dauphin A, Calmus Y, Blanchet B.In vitro influence of fatty acids and bilirubin on binding of mycophenolic acid to human serum albumin.pubmed
2011Benaboud S, Ekouevi DK, Urien S, Rey E, Arrive E, Blanche S, Gray G, Sim KL, Avit D, McIntyre J, Nerrienet E, Dabis F, Treluyer JM, Hirt D; TEmAA ANRS 12109 Study Group.Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates.pubmed
2011Journot V, Pignon JP, Gaultier C, Daurat V, Bouxin-Metro A, Giraudeau B, Preux PM, Treluyer JM, Chevret S, Plättner V, Thalamas C, Clisant S, Ravaud P, Chêne G; Optimon Collaborative Group.Validation of a risk-assessment scale and a risk-adapted monitoring plan for academic clinical research studies--the Pre-Optimon study.pubmed
2010Benkali K, Rostaing L, Premaud A, Woillard JB, Saint-Marcoux F, Urien S, Kamar N, Marquet P, Rousseau A.Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation.pubmed
2010Bouazza N, Hirt D, Bardin C, Diagbouga S, Nacro B, Hien H, Zoure E, Rouet F, Ouiminga A, Blanche S, Van De Perre P, Treluyer JM, Msellati P, Urien S.Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children?pubmed
2011Urien S, Doz F, Giraud C, Rey E, Gentet JC, Chastagner P, Vassal G, Corradini N, Auvrignon A, Leblond P, Rubie H, Treluyer JM.Developmental pharmacokinetics of etoposide in 67 children: lack of dexamethasone effect.pubmed
2010Giraud C, Manceau S, Treluyer JM.ABC transporters in human lymphocytes: expression, activity and role, modulating factors and consequences for antiretroviral therapies.pubmed
2010Hirt D, Fonsart J, Menet MC, Debray M, Noble F, Declèves X, Scherrmann JM.Population pharmacokinetics of 3,4-methylenedioxymethamphetamine and main metabolites in rats.pubmed
2009Ceccaldi PF, Gavard L, Mandelbrot L, Rey E, Farinotti R, Treluyer JM, Gil S.Functional role of p-glycoprotein and binding protein effect on the placental transfer of lopinavir/ritonavir in the ex vivo human perfusion model.pubmed
2009Bouillon-Pichault M, Jullien V, Piketty C, Viard JP, Morini JP, Chhun S, Krivine A, Salmon D, Dupin N, Weiss L, Lortholary O, Pons G, Launay O, Treluyer JM.A population analysis of weight-related differences in lopinavir pharmacokinetics and possible consequences for protease inhibitor-naive and -experienced patients.pubmed
2010Giraud C, Manceau S, Declèves X, Goffinet F, Morini JP, Chappuy H, Batteux F, Chouzenoux S, Yousif S, Scherrmann JM, Blanche S, Treluyer JM.Influence of development, HIV infection, and antiretroviral therapies on the gene expression profiles of ABC transporters in human lymphocytes.pubmed
2009Hirt D, Richardet JP, Urien S, Poupon J, Sogni P, Batteux F, Laurent A, Pavlovic S, Debray M, Treluyer JM, Weill B.Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis.pubmed
2009Fonsart J, Menet MC, Debray M, Hirt D, Noble F, Scherrmann JM, Declèves X.Sprague-Dawley rats display sex-linked differences in the pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolite 3,4-methylenedioxyamphetamine (MDA).pubmed
2009Duval X, Mentre F, Rey E, Auleley S, Peytavin G, Biour M, Metro A, Goujard C, Taburet AM, Lascoux C, Panhard X, Treluyer JM, Salmon-Ceron D; Cophar 2 Study Group.Benefit of therapeutic drug monitoring of protease inhibitors in HIV-infected patients depends on PI used in HAART regimen--ANRS 111 trial.pubmed
2009Hirt D, Urien S, Olivier M, Peyrière H, Nacro B, Diagbouga S, Zoure E, Rouet F, Hien H, Msellati P, Van De Perre P, Treluyer JM.Is the recommended dose of efavirenz optimal in young West African human immunodeficiency virus-infected children?pubmed
2009Abboud I, Lerolle N, Urien S, Tadie JM, Leviel F, Fagon JY, Faisy C.Pharmacokinetics of epinephrine in patients with septic shock: modelization and interaction with endogenous neurohormonal status.pubmed
2009Hirt D, Bardin C, Diagbouga S, Nacro B, Hien H, Zoure E, Rouet F, Ouiminga A, Urien S, Foulongne V, Van De Perre P, Treluyer JM, Msellati P.Didanosine population pharmacokinetics in West African human immunodeficiency virus-infected children administered once-daily tablets in relation to efficacy after one year of treatment.pubmed
2009Bertrand J, Treluyer JM, Panhard X, Tran A, Auleley S, Rey E, Salmon-Ceron D, Duval X, Mentre F; COPHAR2-ANRS 111 Study Group.Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART.pubmed
2009Abou Hammoud H, Simon N, Urien S, Riou B, Lechat P, Aubrun F.Intravenous morphine titration in immediate postoperative pain management: population kinetic-pharmacodynamic and logistic regression analysis.pubmed
2009Bouillon-Pichault M, Jullien V, Azria E, Pannier E, Firtion G, Krivine A, Compagnucci A, Taulera O, Finkielsztejn L, Chhun S, Pons G, Launay O, Treluyer JM.Population analysis of the pregnancy-related modifications in lopinavir pharmacokinetics and their possible consequences for dose adjustment.pubmed
2009Fuchs H, Tillement JP, Urien S, Greischel A, Roth W.Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans.pubmed
2009Hirt D, Urien S, Rey E, Arrive E, Ekouevi DK, Coffie P, Leang SK, Lalsab S, Avit D, Nerrienet E, McIntyre J, Blanche S, Dabis F, Treluyer JM.Population pharmacokinetics of emtricitabine in human immunodeficiency virus type 1-infected pregnant women and their neonates.pubmed
2009Giraud C, Declèves X, Perrot JY, Manceau S, Pannier E, Firtion G, Morini JP, Chappuy H, Batteux F, Chouzenoux S, Scherrmann JM, Blanche S, Treluyer JM.High levels of P-glycoprotein activity in human lymphocytes in the first 6 months of life.pubmed
2009Hirt D, Urien S, Ekouevi DK, Rey E, Arrive E, Blanche S, Amani-Bosse C, Nerrienet E, Gray G, Kone M, Leang SK, McIntyre J, Dabis F, Treluyer JM; ANRS 12109.Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109).pubmed
2008Cressey TR, Green H, Khoo S, Treluyer JM, Compagnucci A, Saidi Y, Lallemant M, Gibb DM, Burger DM; Paediatric European Network for Treatment of AIDS II Study Group.Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children.pubmed
2008Hirt D, Van Overmeire B, Treluyer JM, Langhendries JP, Marguglio A, Eisinger MJ, Schepens P, Urien S.An optimized ibuprofen dosing scheme for preterm neonates with patent ductus arteriosus, based on a population pharmacokinetic and pharmacodynamic study.pubmed
2008Brain EG, Rezai K, Lokiec F, Gutierrez M, Urien S.Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide according to continuous or short infusion schedules: an n = 1 randomized study.pubmed
2008Semmar N, Urien S, Bruguerolle B, Simon N.Independent-model diagnostics for a priori identification and interpretation of outliers from a full pharmacokinetic database: correspondence analysis, Mahalanobis distance and Andrews curves.pubmed
2007Giton F, Urien S, Born C, Tichet J, Guechot J, Callebert J, Bronsard F, Raynaud JP, Fiet J.Determination of bioavailable testosterone [non sex hormone binding globulin (SHBG)-bound testosterone] in a population of healthy French men: influence of androstenediol on testosterone binding to SHBG.pubmed
2008Hirt D, Mentre F, Tran A, Rey E, Auleley S, Salmon D, Duval X, Treluyer JM; COPHAR2- ANRS Study Group.Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients.pubmed
2008Mir O, Berveiller P, Ropert S, Goffinet F, Pons G, Treluyer JM, Goldwasser F.Emerging therapeutic options for breast cancer chemotherapy during pregnancy.pubmed
2007Hirt D, Urien S, Jullien V, Firtion G, Chappuy H, Rey E, Pons G, Mandelbrot L, Treluyer JM.Pharmacokinetic modelling of the placental transfer of nelfinavir and its M8 metabolite: a population study using 75 maternal-cord plasma samples.pubmed
2008Tran A, Bournerias F, Le Beller C, Mir O, Rey E, Pons G, Delahousse M, Treluyer JM.Serious haematological toxicity of cyclophosphamide in relation to CYP2B6, GSTA1 and GSTP1 polymorphisms.pubmed
2007Mir O, Ropert S, Alexandre J, Goldwasser F, Treluyer JM.CYP3A4/5 and pharmacogenetics in patients with sarcoma.pubmed
2007Puisset F, Alexandre J, Treluyer JM, Raoul V, Roche H, Goldwasser F, Chatelut E.Clinical pharmacodynamic factors in docetaxel toxicity.pubmed
2007Antignac M, Barrou B, Farinotti R, Lechat P, Urien S.Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients.pubmed
2007Vespa PM, O'Phelan K, McArthur D, Miller C, Eliseo M, Hirt D, Glenn T, Hovda DA.Pericontusional brain tissue exhibits persistent elevation of lactate/pyruvate ratio independent of cerebral perfusion pressure.pubmed
2007Jullien V, Raïs A, Urien S, Dimet J, Delaugerre C, Bouillon-Pichault M, Rey E, Pons G, Blanche S, Treluyer JM.Age-related differences in the pharmacokinetics of stavudine in 272 children from birth to 16 years: a population analysis.pubmed
2007Brain EG, Rezai K, Weill S, Gauzan MF, Santoni J, Besse B, Goupil A, Turpin F, Urien S, Lokiec F.Variations in schedules of ifosfamide administration: a better understanding of its implications on pharmacokinetics through a randomized cross-over study.pubmed
2006Jullien V, Urien S, Hirt D, Delaugerre C, Rey E, Teglas JP, Vaz P, Rouzioux C, Chaix ML, Macassa E, Firtion G, Pons G, Blanche S, Treluyer JM.Population analysis of weight-, age-, and sex-related differences in the pharmacokinetics of lopinavir in children from birth to 18 years.pubmed
2005Servais A, Lechat P, Zahr N, Urien S, Aymard G, Jaudon MC, Deray G, Isnard Bagnis C.[Tubular transporters OAT1 and MRP2 and clearance of adefovir].pubmed
2006Tran A, Jullien V, Alexandre J, Rey E, Rabillon F, Girre V, Dieras V, Pons G, Goldwasser F, Treluyer JM.Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms.pubmed
2006Servais A, Lechat P, Zahr N, Urien S, Aymard G, Jaudon MC, Deray G, Isnard Bagnis C.Tubular transporters and clearance of adefovir.pubmed
2006Hirt D, Treluyer JM, Jullien V, Firtion G, Chappuy H, Rey E, Pons G, Mandelbrot L, Urien S.Pregnancy-related effects on nelfinavir-M8 pharmacokinetics: a population study with 133 women.pubmed
2006Faltaos DW, Urien S, Carreau V, Chauvenet M, Hulot JS, Giral P, Bruckert E, Lechat P.Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients.pubmed
2006Simon N, Dussol B, Sampol E, Purgus R, Brunet P, Lacarelle B, Berland Y, Bruguerolle B, Urien S.Population pharmacokinetics of ceftriaxone and pharmacodynamic considerations in haemodialysed patients.pubmed
2006Faltaos DW, Hulot JS, Urien S, Morel V, Kaloshi G, Fernandez C, Xuan kH, Leblond V, Lechat P.Population pharmacokinetic study of methotrexate in patients with lymphoid malignancy.pubmed
2006Hirt D, Urien S, Jullien V, Firtion G, Rey E, Pons G, Blanche S, Treluyer JM.Age-related effects on nelfinavir and M8 pharmacokinetics: a population study with 182 children.pubmed
2005Urien S, Rezaí K, Lokiec F.Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer.pubmed
2005Sanchez-Pena P, Hulot JS, Urien S, Ankri A, Collet JP, Choussat R, Lechat P, Montalescot G.Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis.pubmed
2005Le Jouan M, Jullien V, Tetanye E, Tran A, Rey E, Treluyer JM, Tod M, Pons G.Quinine pharmacokinetics and pharmacodynamics in children with malaria caused by Plasmodium falciparum.pubmed
2005Jullien V, Treluyer JM, Rey E, Jaffray P, Krivine A, Moachon L, Lillo-Le Louet A, Lescoat A, Dupin N, Salmon D, Pons G, Urien S.Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy.pubmed
2005Antignac M, Hulot JS, Boleslawski E, Hannoun L, Touitou Y, Farinotti R, Lechat P, Urien S.Population pharmacokinetics of tacrolimus in full liver transplant patients: modelling of the post-operative clearance.pubmed
2005Hulot JS, Montalescot G, Lechat P, Collet JP, Ankri A, Urien S.Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome.pubmed
2005Desfrere L, Zohar S, Morville P, Brunhes A, Chevret S, Pons G, Moriette G, Rey E, Treluyer JM.Dose-finding study of ibuprofen in patent ductus arteriosus using the continual reassessment method.pubmed
2005Lentz F, Tran A, Rey E, Pons G, Treluyer JM.Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications.pubmed
2005Jullien V, Urien S, Chappuy H, Dimet J, Rey E, Pons G, Blanche S, Treluyer JM.Abacavir pharmacokinetics in human immunodeficiency virus-infected children ranging in age from 1 month to 16 years: a population analysis.pubmed
2005Jullien V, Treluyer JM, Chappuy H, Dimet J, Rey E, Dupin N, Salmon D, Pons G, Urien S.Weight related differences in the pharmacokinetics of abacavir in HIV-infected patients.pubmed
2005Germann N, Urien S, Rodgers AH, Ratterree M, Struck RF, Waud WR, Serota DG, Bastian G, Jursic BS, Morgan LR.Comparative preclinical toxicology and pharmacology of isophosphoramide mustard, the active metabolite of ifosfamide.pubmed
2004Chappuy H, Treluyer JM, Jullien V, Dimet J, Rey E, Fouche M, Firtion G, Pons G, Mandelbrot L.Maternal-fetal transfer and amniotic fluid accumulation of nucleoside analogue reverse transcriptase inhibitors in human immunodeficiency virus-infected pregnant women.pubmed
2004Delaugerre C, Teglas JP, Treluyer JM, Vaz P, Jullien V, Veber F, Rouzioux C, Chaix ML, Blanche S.Predictive factors of virologic success in HIV-1-infected children treated with lopinavir/ritonavir.pubmed
2004Ghosn J, Chaix ML, Peytavin G, Rey E, Bresson JL, Goujard C, Katlama C, Viard JP, Treluyer JM, Rouzioux C.Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men.pubmed
2004Burger DM, Bergshoeff AS, De Groot R, Gibb D, Walker S, Treluyer JM, Hoetelmans RM; PENTA 5 study group.Maintaining the nelfinavir trough concentration above 0.8 mg/L improves virologic response in HIV-1-infected children.pubmed
2005Urien S, Brain E, Bugat R, Pivot X, Lochon I, Van ML, Vauzelle F, Lokiec F.Pharmacokinetics of platinum after oral or intravenous cisplatin: a phase 1 study in 32 adult patients.pubmed
2004Gil-Delgado MA, Bastian G, Guinet F, Spano JP, Taillibert S, Rocher MA, Castaing D, Adam R, Urien S, Bismuth H, Khayat D.Oxaliplatin plus irinotecan and FU-FOL combination and pharmacokinetic analysis in advanced colorectal cancer patients.pubmed
2004Hulot JS, Vantelon C, Urien S, Bouzamondo A, Mahe I, Ankri A, Montalescot G, Lechat P.Effect of renal function on the pharmacokinetics of enoxaparin and consequences on dose adjustment.pubmed
2004Urien S, Lokiec F.Population pharmacokinetics of total and unbound plasma cisplatin in adult patients.pubmed
2004Trenque T, Simon N, Villena I, Chemla C, Quereux C, Leroux B, Jaussaud R, Remy G, Dupouy D, Millart H, Pinon JM, Urien S.Population pharmacokinetics of pyrimethamine and sulfadoxine in children with congenital toxoplasmosis.pubmed
2004Treluyer JM, Andre C, Carp PF, Chalumeau M, Tonnelier S, Cuq C, Kalifa G, Pons G, Adamsbaum C.Sedation in children undergoing CT scan or MRI: effect of time-course and tolerance of rectal chloral hydrate.pubmed
2004Decaudin D, Etienne MC, De Cremoux P, Maciorowski Z, Vantelon JM, Voog E, Urien S, Tran-Perennou C, Renee N, Vielh P, Nemati F, Pouillart P.Multicenter phase II feasibility trial of high-dose tamoxifen in patients with refractory or relapsed multiple myeloma.pubmed
2004de Spirlet M, Treluyer JM, Chevret S, Rey E, Tournaire M, Cabrol D, Pons G.Tocolytic effects of intravenous nitroglycerin.pubmed
2004Urien S, Laurent N, Barre J, Druguet M, Bouvier D'yvoire M, Maire P.Pharmacokinetic modelling of cefotaxime and desacetylcefotaxime--a population study in 25 elderly patients.pubmed
2004Castagne V, Bonhomme-Faivre L, Urien S, Ben Reguiga M, Soursac M, Gimenez F, Farinotti R.Effect of recombinant interleukin-2 pretreatment on oral and intravenous digoxin pharmacokinetics and P-glycoprotein activity in mice.pubmed
2003Cazali N, Tran A, Treluyer JM, Rey E, d'Athis P, Vincent J, Pons G.Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human.pubmed
2004Deporte-Fety R, Simon N, Fumoleau P, Campone M, Kerbrat P, Bonneterre J, Fargeot P, Urien S.Population pharmacokinetics of short intravenous vinorelbine infusions in patients with metastatic breast cancer.pubmed
2003Bastian G, Barrail A, Urien S.Population pharmacokinetics of oxaliplatin in patients with metastatic cancer.pubmed
2003Simon N, Sampol E, Albanese J, Martin C, Arvis P, Urien S, Lacarelle B, Bruguerolle B.Population pharmacokinetics of moxifloxacin in plasma and bronchial secretions in patients with severe bronchopneumonia.pubmed
2003Rubie H, Doz F, Vassal G, Chastagner P, Gentet JC, Urien S, Bastian G, Drouard-Troalen L, Barberi-Heyob M, Catalin J, Chatelut E; Pharmacology Group of the Societe Française de Pediatrie Oncologique.Individual dosing of carboplatin based on drug monitoring in children receiving high-dose chemotherapy.pubmed
2003Urien S, Alexandre J, Raymond E, Brain E, Smith S, Shah A, Cvitkovic E, Lokiec F.Phase I population pharmacokinetics of irofulven.pubmed
2003Urien S, Fumoleau P, Campone M, Kerbrat P, Bonneterre J, Fargeot P, Deporte-Fety R.Modelling of ftorafur and 5-fluorouracil pharmacokinetics following oral UFT administration. A population study in 30 patients with advanced breast cancer.pubmed
2003Salmon-Ceron D, Lassalle R, Pruvost A, Benech H, Bouvier-Alias M, Payan C, Goujard C, Bonnet E, Zoulim F, Morlat P, Sogni P, Perusat S, Treluyer JM, Chêne G; CORIST-ANRS HC1 Study Group.Interferon-ribavirin in association with stavudine has no impact on plasma human immunodeficiency virus (HIV) type 1 level in patients coinfected with HIV and hepatitis C virus: a CORIST-ANRS HC1 trial.pubmed
2003Gendrel D, Treluyer JM, Richard-Lenoble D.Parasitic diarrhea in normal and malnourished children.pubmed
2003Treluyer JM, Bowers G, Cazali N, Sonnier M, Rey E, Pons G, Cresteil T.Oxidative metabolism of amprenavir in the human liver. Effect of the CYP3A maturation.pubmed
2003Simon N, Morin C, Urien S, Tillement JP, Bruguerolle B.Tacrolimus and sirolimus decrease oxidative phosphorylation of isolated rat kidney mitochondria.pubmed
2003Treluyer JM, Burgard M, Cazali N, Quartier P, Veber F, Rey E, Alkaer G, Rouzioux C, Pons G, Blanche S.Relationship between antiretroviral drug plasma concentrations and viral load in children.pubmed
2002Marchetti P, Urien S, Cappellini GA, Ronzino G, Ficorella C.Weekly administration of paclitaxel: theoretical and clinical basis.pubmed
2002Dailly E, Urien S, Chanut E, Claudel B, Guerra N, Femandez C, Jolliet P, Bourin M.Evidence from a population pharmacokinetics analysis for a major effect of CYP1A2 activity on inter- and intraindividual variations of clozapine clearance.pubmed
2002Urien S, Doz F, Namouni F, Bastian G.Pharmacokinetic modelling of total and unbound plasma carboplatin--a population study in 75 children.pubmed
2002Treluyer JM, Merle Y, Tonnelier S, Rey E, Pons G.Nonparametric population pharmacokinetic analysis of amikacin in neonates, infants, and children.pubmed
2002Bonhomme-Faivre L, Pelloquin A, Tardivel S, Urien S, Mathieu MC, Castagne V, Lacour B, Farinotti R.Recombinant interleukin-2 treatment decreases P-glycoprotein activity and paclitaxel metabolism in mice.pubmed
2001Rey E, Gendrel D, Treluyer JM, Tran A, Pariente-Khayat A, d'Athis P, Pons G.Isoniazid pharmacokinetics in children according to acetylator phenotype.pubmed
2001Treluyer JM, Rey E, Sonnier M, Pons G, Cresteil T.Evidence of impaired cisapride metabolism in neonates.pubmed
2001Hamdan M, Urien S, Le Louet H, Tillement JP, Morin D.Inhibition of mitochondrial carnitine palmitoyltransferase-1 by a trimetazidine derivative, S-15176.pubmed
2001Mouly S, Aymard G, Tillement JP, Caulin C, Bergmann JF, Urien S.Increased oral ganciclovir bioavailability in HIV-infected patients with chronic diarrhoea and wasting syndrome--a population pharmacokinetic study.pubmed
2001Tran A, Treluyer JM, Rey E, Barbet J, Ferracci G, d'Athis P, Vincent J, Pons G.Protective effect of stiripentol on acetaminophen-induced hepatotoxicity in rat.pubmed
2000Treluyer JM, Pons G.[What's new in pediatric pharmacology?].pubmed
2000Treluyer JM.[The value of plasma antiretroviral drug monitoring in the management of HIV infected patients].pubmed
2000Treluyer JM, Merle Y, Semlali A, Pons G.Population pharmacokinetic analysis of netilmicin in neonates and infants with use of a nonparametric method.pubmed
2000Combes O, Barre J, Duche JC, Vernillet L, Archimbaud Y, Marietta MP, Tillement JP, Urien S.In vitro binding and partitioning of irinotecan (CPT-11) and its metabolite, SN-38, in human blood.pubmed
2000Morin D, Sapena R, Tillement JP, Urien S.Evidence for different interactions between beta(1)- and beta(2)-adrenoceptor subtypes with adenylyl cyclase in the rat brain: a concentration-response study using forskolin.pubmed
1999Urien S, Tillement JP, Ganem B, Kuch MD.A pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effects of cetirizine.pubmed
1999Pariente-Khayat A, Treluyer JM, Rey E, Mokhtari M, Werner E, Jouvet P, d'Athis P, Wood C, Hubert P, Hotellier F, Olive G, Pons G.Pharmacokinetics and tolerance of flunitrazepam in neonates and in infants.pubmed
1999Rey E, Treluyer JM, Pons G.Pharmacokinetic optimization of benzodiazepine therapy for acute seizures. Focus on delivery routes.pubmed
1999Passe P, Delepine N, Arnaud P, Urien S, Delepine G, Traore F, Desbois JC, Brion F.Pharmacokinetic modelling of ifosfamide administered by continuous infusion on 5 days at the dose of 6 g/m2.pubmed
1998Rey E, Treluyer JM, Pons G.Drug disposition in cystic fibrosis.pubmed
1998Doz F, Urien S, Chatelut E, Michon J, Rubie H, Zucker JM, Canal P, Bastian G.A limited-sampling method for evaluation of the area under the curve of ultrafilterable carboplatin in children.pubmed
1998Dailly E, Urien S, Tillement JP.Chain-breaking antioxidants and ferriheme-bound drugs are synergistic inhibitors of erythrocyte membrane peroxidation.pubmed
1998Bertelli AA, Giovannini L, Stradi R, Urien S, Tillement JP, Bertelli A.Evaluation of kinetic parameters of natural phytoalexin in resveratrol orally administered in wine to rats.pubmed
1998Pagliara A, Testa B, Carrupt PA, Jolliet P, Morin C, Morin D, Urien S, Tillement JP, Rihoux JP.Molecular properties and pharmacokinetic behavior of cetirizine, a zwitterionic H1-receptor antagonist.pubmed
1998Simon N, Dailly E, Combes O, Malaurie E, Lemaire M, Tillement JP, Urien S.Role of lipoproteins in the plasma binding of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin.pubmed
1997Russo H, Dubboin MP, Bressolle F, Urien S.Time-dependent pharmacokinetics of high dose thiopental infusion in intensive care patients.pubmed
1997Treluyer JM, Gueret G, Cheron G, Sonnier M, Cresteil T.Developmental expression of CYP2C and CYP2C-dependent activities in the human liver: in-vivo/in-vitro correlation and inducibility.pubmed
1997Valente D, Delaforge M, Urien S, Guivarc'h D, Vienet R, Grognet JM, Ezan E.Metabolite involvement in bromocriptine-induced prolactin inhibition in rats.pubmed
1997Russo H, Simon N, Duboin MP, Urien S.Population pharmacokinetics of high-dose thiopental in patients with cerebral injuries.pubmed
1997Jolliet P, Simon N, Bree F, Urien S, Pagliara A, Carrupt PA, Testa B, Tillement JP.Blood-to-brain transfer of various oxicams: effects of plasma binding on their brain delivery.pubmed
1996Treluyer JM, Roux A, Mugnier C, Flouvat B, Lagardère B.Metabolism of quinine in children with global malnutrition.pubmed
1996Depres-Brummer P, Metzger G, Morin D, Urien S, Touitou Y, Tillement JP, Claustrat B, Levi F.Pharmacokinetically guided melatonin scheduling in rats with circadian system suppression.pubmed
1996Treluyer JM, Cheron G, Sonnier M, Cresteil T.Cytochrome P-450 expression in sudden infant death syndrome.pubmed
1996Desoize B, Dufour R, Urien S, Kaltenbach M, Colin P.Evaluation of two dose individualisation methods for carboplatin.pubmed
1996Bertelli AA, Giovannini L, Stradi R, Urien S, Tillement JP, Bertelli A.Kinetics of trans- and cis-resveratrol (3,4',5-trihydroxystilbene) after red wine oral administration in rats.pubmed
1996Chassany O, Urien S, Claudepierre P, Bastian G, Tillement JP.Comparative serum protein binding of anthracycline derivatives.pubmed
1996Mouawad R, Urien S, Soubrane C, Khayat D, Brandt R, Tillement JP, Bastian G.Comparison of the uptake of retinoids 13-cis-retinoic acid and Ro 13-6298 delivered to HL-60 cells by serum albumin or low-density lipoprotein.pubmed
1995Urien S.MicroPharm-K, a microcomputer interactive program for the analysis and simulation of pharmacokinetic processes.pubmed
1995Urien S, Giroud Y, Tsai RS, Carrupt PA, Bree F, Testa B, Tillement JP.Mechanism of ligand binding to alpha 1-acid glycoprotein (orosomucoid): correlated thermodynamic factors and molecular parameters of polarity.pubmed
1994Desoize B, Dumont P, Manot L, Urien S, Dufour R, Berthiot G.Comparison of two dose prediction models for cisplatin.pubmed
1994Bard JM, Urien S, Fruchart JC, Tillement JP.Location of probucol in lipoproteins inferred from compositional analysis of lipoprotein particles. An in-vitro study.pubmed
1994Urien S, Nguyen P, Berlioz S, Bree F, Vacherot F, Tillement JP.Characterization of discrete classes of binding sites of human serum albumin by application of thermodynamic principles.pubmed
1994Cazeneuve C, Pons G, Rey E, Treluyer JM, Cresteil T, Thiroux G, D'Athis P, Olive G.Biotransformation of caffeine in human liver microsomes from foetuses, neonates, infants and adults.pubmed
1994Claudepierre P, Urien S, Chevalier X, Chassany O, Larget-Piet B, Tillement JP.Methotrexate serum binding in rheumatoid arthritis.pubmed
1994Claudepierre P, Urien S, Chassany O, Tillement JP.Analysis of free fatty acid effect on methotrexate binding to albumin.pubmed
1994Cresteil T, Monsarrat B, Alvinerie P, Treluyer JM, Vieira I, Wright M.Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation.pubmed
1994Herve F, Urien S, Albengres E, Duche JC, Tillement JP.Drug binding in plasma. A summary of recent trends in the study of drug and hormone binding.pubmed
1994Urien S, Claudepierre P, Nguyen P, Chassany O, Meyer J, Brandt R, Tillement JP.Binding of retinoid analogues to albumin and lipoproteins of human plasma.pubmed
1993Bree F, Urien S, Nguyen P, Tillement JP, Steiner A, Vallat-Molliet C, Testa B, Visy J, Simonyi M.Human serum albumin conformational changes as induced by tenoxicam and modified by simultaneous diazepam binding.pubmed
1993Sveinbjornsdottir S, Sander JW, Upton D, Thompson PJ, Patsalos PN, Hirt D, Emre M, Lowe D, Duncan JS.The excitatory amino acid antagonist D-CPP-ene (SDZ EAA-494) in patients with epilepsy.pubmed
1993Calès P, Caillau H, Crambes O, Vinel JP, Desmorat H, Rocher I, Jung L, Urien S, Brouard R, Pascal JP.Hemodynamic and pharmacokinetic study of tertatolol in patients with alcoholic cirrhosis and portal hypertension.pubmed
1993Urien S, Bree F, Testa B, Tillement JP.pH-dependence of warfarin binding to alpha 1-acid glycoprotein (orosomucoid).pubmed
1993Urien S, Bree F, Breillout F, Bastian G, Krikorian A, Tillement JP.Vinorelbine high-affinity binding to human platelets and lymphocytes: distribution in human blood.pubmed
1993Muret P, Makki S, Urien S, Agache P, Bechtel P, Tillement JP.Binding of 5-methoxypsoralen to blood fractions. Influence of albumin and free fatty acids: an in vitro study.pubmed
1992Urien S, Claudepierre P, Meyer J, Brandt R, Tillement JP.Comparative binding of etretinate and acitretin to plasma proteins and erythrocytes.pubmed
1992Bree F, Nguyen P, Urien S, Resplandy G, Tillement JP.Specific and high affinity binding of perindoprilat, but not of perindopril to blood ACE.pubmed
1992Bastian G, Urien S, Bree F, Jolliet P, Rocher I, Crambes O, Tillement JP.Stereoselective binding of tertatolol and of 4-hydroxytertatolol to human plasma proteins.pubmed
1991Urien S, Bree F, Testa B, Tillement JP.pH-dependency of basic ligand binding to alpha 1-acid glycoprotein (orosomucoid).pubmed
1991Damaj MI, Urien S, Trouvin JH, Chanut E, Lambrey B, Jacquot C.In vivo evidence for carrier-mediated brain uptake of a new 2-amino-2-oxazoline (COR3224) via the purine transport system in rat.pubmed
1991Treluyer JM, Sultan E, Alexandre JA, Roux A, Flouvat B, Lagardère B.[Pharmacokinetics of aspirin in African children with normal nutrition and malnutrition].pubmed
1990Bree F, Urien S, Nguyen P, Riant P, Albengres E, Tillement JP.A re-evaluation of the HSA-piroxicam interaction.pubmed
1990Maulard C, Urien S, Bastian G, Tillement JP.Binding of retelliptine, a new antitumoral agent, to serum proteins and erythrocytes.pubmed
1990Urien S, Zini R, Lemaire M, Tillement JP.Assessment of cyclosporine A interactions with human plasma lipoproteins in vitro and in vivo in the rat.pubmed
1990Riant P, Bree F, Urien S, Hamberger C, Albengres E, Tillement JP.How chronically administered valproate increases chlordiazepoxide transfer through the blood-brain barrier.pubmed
1989Pinquier JL, Urien S, Chaumet-Riffaud P, Tillement JP.Differences in the serum binding determinants of isradipine and darodipine--consequences for serum protein binding in various diseases.pubmed
1989Essassi D, Urien S, Zini R, Tillement JP.Pipequaline transport from blood to brain and liver: role of plasma protein-bound drug.pubmed
1989Morin D, Zini R, Urien S, Tillement JP.Pharmacological profile of binedaline, a new antidepressant drug.pubmed
1989Bree F, Nguyen P, Albengres E, Urien S, Riant P, Welling PG, Tillement JP.Evidence for isoxicam binding to site I as a primary site and to site II as a secondary site of human serum albumin.pubmed
1989Urien S, Morin D, Tillement JP.Effect of alpha-1-acid glycoprotein, albumin and palmitic acid on the brain and salivary gland extraction of warfarin in rats.pubmed
1989Bree F, Nguyen P, Urien S, Riant P, Albengres E, Fenner H, Tillement JP.Blood distribution of tenoxicam in humans: a particular HSA drug interaction.pubmed
1989Belaiba R, Riant P, Urien S, Bree F, Albengres E, Barre J, Tillement JP.Blood binding and tissue transfer of drugs: the influence of alpha 1 acid glycoprotein binding.pubmed
1988Urien S, Riant P, Renouard A, Coulomb B, Rocher I, Tillement JP.Binding of indapamide to serum proteins and erythrocytes.pubmed
1988Riant P, Urien S, Albengres E, Renouard A, Tillement JP.Effects of the binding of imipramine to erythrocytes and plasma proteins on its transport through the rat blood-brain barrier.pubmed
1988Urien S, Morin D, d'Athis P, Coulomb B, Tillement JP.Serum binding of indapamide in health and disease: primary role of alpha 1-acid glycoprotein.pubmed
1988Pinquier JL, Urien S, Chaumet-Riffaud P, Comte A, Tillement JP.Binding of [3H]isradipine (PN 200-110) on smooth muscle cell membranes from different bovine arteries.pubmed
1988Barre J, Urien S, Albengres E, Tillement JP.Plasma and tissue binding as determinants of drug body distribution. Possible applications to toxicological studies.pubmed
1988Hamberger C, Urien S, Barre J, Brandebourger M, Lemaire M, Lang P, Buisson C, Loisance D, Cachera JP, Lagrue G, et al.Distribution of cyclosporin A between blood cells and plasma of cardiac and renal transplant recipients.pubmed
1988Tillement JP, Urien S, Chaumet-Riffaud P, Riant P, Bree F, Morin D, Albengres E, Barre J.Blood binding and tissue uptake of drugs. Recent advances and perspectives.pubmed
1988Albengres E, Pinquier JL, Riant P, Bree F, Urien S, Barre J, Tillement JP.Pharmacological criteria for risk-benefit evaluation of NSAIDs.pubmed
1988Urien S, Morin D, Renouard A, Rocher I, Tillement JP.Variation in serum binding of tertatolol mediated by disease-induced modification of alpha-acid glycoprotein concentration.pubmed
1987Essassi D, Zini R, Hamberger C, Urien S, Rougeot C, Uzan A, Tillement JP.Binding in vitro of pipequaline (45319 RP) onto plasma proteins and blood cells in man.pubmed
1987Hamberger C, Urien S, Essassi D, Grimaldi B, Barre J, Taiclet A, Thenot JP, Tillement JP.Effect of erythrocytes and plasma protein binding on the transport of progabide and SL 75102 through the rat blood-brain barrier.pubmed
1987Urien S, Pinquier JL, Paquette B, Chaumet-Riffaud P, Kiechel JR, Tillement JP.Effect of the binding of isradipine and darodipine to different plasma proteins on their transfer through the rat blood-brain barrier. Drug binding to lipoproteins does not limit the transfer of drug.pubmed
1987Hamberger C, Barre J, Brandebourger M, Urien S, Taiclet A, Thenot JP, Tillement JP.Progabide and SL 75102 binding to plasma proteins and red blood cells in humans.pubmed
1987Albengres E, Urien S, Riant P, Marcel GA, Tillement JP.Binding of two anthranilic acid derivatives to human albumin, erythrocytes, and lipoproteins: evidence for glafenic acid high affinity binding.pubmed
1987Tari C, Fournier N, Ducet G, Crevat A, Albengres E, Urien S, Tillement JP.Comparative study of bepridil and nicardipine action on respiration and calcium transport in mitochondria.pubmed
1986Riant P, Urien S, Albengres E, Duche JC, Tillement JP.High plasma protein binding as a parameter in the selection of betablockers for lactating women.pubmed
1986Urien S, Albengres E, Pinquier JL, Tillement JP.Role of alpha-1 acid glycoprotein, albumin, and nonesterified fatty acids in serum binding of apazone and warfarin.pubmed
1985Urien S, Albengres E, Comte A, Kiechel JR, Tillement JP.Plasma protein binding and erythrocyte partitioning of nicardipine in vitro.pubmed
1985Chamouard JM, Barre J, Urien S, Houin G, Tillement JP.Diclofenac binding to albumin and lipoproteins in human serum.pubmed
1985Albengres E, Urien S, Tillement JP, Oury P, Decourt S, Flouvat B, Drieu K.Interactions between smectite, a mucus stabilizer, and acidic and basic drugs. In vitro and in vivo studies.pubmed
1984Urien S, Riant P, Albengres E, Brioude R, Tillement JP.In vitro studies on the distribution of probucol among human plasma lipoproteins.pubmed
1984Urien S, D'Athis P, Tillement JP.The binding of aryl carboxylic acid derivatives to human serum albumin--a structure-activity study.pubmed
1982Urien S, Albengres E, Zini R, Tillement JP.Evidence for binding of certain acidic drugs to alpha 1-acid glycoprotein.pubmed
1981Urien S, Albengres E, Tillement JP.Serum protein binding of valproic acid in healthy subjects and in patients with liver disease.pubmed
1979Tillement JP, Albengres E, Urien S.Methodological aspects of the evaluation of the binding of drugs to plasma and tissue proteins.pubmed